Survodutide
Investigational once-weekly dual glucagon / GLP-1 receptor agonist in late-stage development for obesity, overweight-related disease, and MASH-associated programs.
Survodutide is one of the most important late-stage metabolic peptides in current development. Co-developed by Boehringer Ingelheim and Zealand Pharma, it combines GLP-1 receptor agonism with glucagon receptor agonism to create a dual-pathway metabolic and hepatic program. It should be treated as a serious clinical-development asset rather than as a speculative research peptide. The repository should emphasize that this is not yet an approved medicine as of the current update, but it is firmly inside major-company Phase 3 development territory.
Important names include survodutide and the development code BI 456906. It belongs to the dual incretin / glucagon agonist family and is often grouped with other next-generation obesity or MASH candidates. Because several drugs in this class have overlapping narratives, the identity section should cross-reference its sponsors and trial-program names to prevent confusion with mazdutide, retatrutide, and other multi-agonist peptides.
3. Sequence and structure
Public-facing development materials describe survodutide as a long-acting modified peptide engineered for dual GLP-1R and GCGR agonism and once-weekly administration. Full chemistry detail is not always foregrounded in clinical-development summaries, so the repository should avoid pretending the entire sequence is settled from front-page materials alone unless patent-level sources are curated. What matters operationally is that it is a purpose-built long-acting dual agonist peptide, not a simple native-hormone fragment.
Survodutide combines GLP-1 receptor agonism, which supports appetite suppression and glucose-relevant signaling, with glucagon receptor agonism, which can increase energy expenditure and influence hepatic lipid metabolism. This duality is what makes the compound attractive in obesity and liver-disease development. Mechanistically it belongs to the more ambitious next-generation metabolic peptide class where weight reduction and liver benefits may be pursued together.
Current development is focused on obesity, overweight-related disease, and liver-related metabolic disease including MASH / MASLD-associated programs. The obesity program now includes large Phase 3 SYNCHRONIZE studies, and cardiovascular-outcomes framing has also entered the development story. Repository use-case labeling should remain clinical-development based, not community-usage based, because this is a sponsor-driven investigational drug rather than a gray-market peptide.
Survodutide is designed for once-weekly subcutaneous administration, which signals a long-acting engineered exposure profile. As with related multi-agonist peptides, the most practical PK summary is titration-friendly weekly dosing with sustained target engagement rather than rapid short-peptide turnover. Public clinical-development sources support class-consistent prolonged activity, though detailed label-grade ADME is not available because the drug is not yet approved.
The efficacy story is strong for an investigational agent. Phase 2 results have shown clinically important weight-loss effects and promising liver-disease signals, which is why the compound progressed into a broad late-stage program. It still remains investigational, so the repository should not write as if outcomes are final, but survodutide clearly sits in the upper tier of current obesity / MASH pipeline relevance.
Safety looks broadly consistent with an intensive metabolic peptide class, especially gastrointestinal tolerability issues during escalation, but definitive long-term judgment awaits Phase 3 readouts and regulatory review. The dual glucagon component also makes the compound conceptually distinct from pure GLP-1 drugs, so class comparisons should be made carefully. At this stage the correct label is promising but still investigational.
Clinical development uses once-weekly subcutaneous dosing with titration-based regimens intended to improve tolerability and reach therapeutic exposure gradually. There is no approved commercial dosing schedule yet. Repository entries should therefore frame administration in trial terms rather than consumer terms.
UNVERIFIED RESEARCHER-REPORTED DOSING INFORMATION
The following dosing information has been compiled from community forums, researcher discussions, and gray-market sources. This information has NOT been verified through peer-reviewed scientific studies or clinical trials. It does NOT constitute medical advice, a prescription, or a recommendation for human use.
This data is presented solely for informational and educational purposes to document what is commonly discussed in research communities. Dosing protocols may be inaccurate, dangerous, or based on anecdotal reports with no scientific validation. Individual responses vary significantly, and unregulated compounds carry inherent risks including contamination, mislabeling, and unknown side effects.
Always consult qualified medical professionals before making any health-related decisions. The repository maintainers assume no liability for the use or misuse of this information.
Researcher-Reported Dosing Protocols
Common Dose Range: 0.6mg - 4.5mg
Administration Route: Subcutaneous
Frequency: Once per week
Timing: Take on the same day every week.
Schedule / Protocol: Continuous, with dose escalation every 4-5 weeks.
Dose Escalation: Start at 0.6mg for weeks 1-4 to minimize GI side effects. Gradually titrate up every 4-5 weeks to a maximum of 4.5mg.
Additional Notes: Reconstitute with 1mL bacteriostatic water, which equals 0.06mg/unit.
This researcher-reported dosing information was compiled from unverified community sources and does not represent validated scientific or medical guidance.
Survodutide has an active Phase 3 development footprint including the SYNCHRONIZE obesity studies and related cardiovascular- and liver-relevant programs. Current public materials make it one of the most visible next-wave obesity peptide candidates after tirzepatide and in parallel with other multi-agonist strategies. Trial-program names should be stored explicitly because they are likely to remain the main tracking framework until approval or discontinuation.
As of March 2026, survodutide remains investigational and no FDA or EMA approval was identified. However, it is clearly in late-stage development and should not be grouped with loose gray-market peptides. The correct classification is late-stage sponsor-backed clinical-development peptide.
13. References and source quality
Highest-value sources include Boehringer Ingelheim and Zealand Pharma trial-development materials, ClinicalTrials.gov records, and peer-reviewed publications describing the Phase 3 program design and earlier efficacy results. Source quality is high for development status and moderate for final clinical conclusions because approval decisions have not yet occurred. This is a strong pipeline entry with good primary-source visibility.
The product should be treated as a proprietary long-acting injectable peptide formulation. Manufacturing notes should focus on peptide-drug substance engineering, once-weekly delivery design, and sponsor-controlled clinical product presentation rather than on unverified vendor formulations. As with other late-stage incretin-pathway agents, device and formulation details may become much more important after approval.
Version 0.1 starter entry created March 14, 2026. Evidence basis for this draft: Boehringer Ingelheim Phase 3 program pages, ClinicalTrials.gov entries, and recent peer-reviewed publications describing the SYNCHRONIZE trials. Recommended future upgrade: add major efficacy readouts as Phase 3 topline data become public.